Trials / Completed
CompletedNCT02872168
Identification of a New Metabolite of Furosemide in Humans
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (actual)
- Sponsor
- Henri Mondor University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Recent in-vitro and in-vivo studies performed by one of the investigators (ESO, ICMPE, UPEC, France) have recently allowed to synthetize a new and easy-to-synthesized chemical compound of the furosemide (pyridinium furosemide) during furosemide degradation by electro-Fenton or bioconversion. The biological properties of pyridinium furosemide are currently under investigation. Furosemide is a diuretics currently used in the treatment of patients with heart failure. The goal of the investigators is to assay pyridinium furosemide in urine of patients treated by furosemide to demonstrate that pyridinium is or not a metabolite of furosemide in humans. This study will contribute to assess the fate of pharmaceutical residues of furosemide in the environment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Not intervention | None. there is no modification in the treatment of patients. A urine collection is carry out in patients during the day of their enrolment. |
Timeline
- Start date
- 2015-06-01
- Primary completion
- 2016-02-01
- Completion
- 2016-02-01
- First posted
- 2016-08-19
- Last updated
- 2016-08-19
Source: ClinicalTrials.gov record NCT02872168. Inclusion in this directory is not an endorsement.